Aspirin is a weak acid that crosses the gastric and intestinal mucosa by passive diffusion while in its lipophilic nature.Omeprazole, a proton pump inhibitor, inhibits gastric acid secretion. We assumed that omeprazole inhibits aspirin absorption, thus reducing its action on platelets. healthy volunteers, with no known peptic disease or bleeding disorders will be enrolled. All volunteers will receive 7 days of Aspirin (100mg) alone, followed by 14 days of Aspirin and Omeprazole 20mg twice daily for 3 days and then 20mg once daily. Blood levels of Aspirin will be determined by High performance liquid chromatography (HPLC), 0, 1, 2, 4, 6, 10, 24 hours after the administration of Aspirin alone on day 7 and Aspirin plus Omeprazole on day 21. Platelet function tests will be determined by platelet-rich plasma aggregometry in response to Arachidonic acid (500mg/ml), Ristocetin (1.5mg/ml) and Adenosine 5'-diphosphate (20mM) on day 0 as baseline and on day 7 and 21 of the study.
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
9
aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
Assaf Harofeh Medical Center
Ẕerifin, Israel
Aspirin Level in Blood (Area Under the Curve)
Aspirins pharmacokinetics: aspirin blood level determined by use of high performance liquid chromatography (HPLC) at baseline, 1, 2,4,6,10 and 24 hours after administration of aspirin on day 7 and on day 21. The area unther the time vs. concentration curve of the reccurent measurments(AUC) reflects bioavailability of aspirin.
Time frame: on day 7,on day 21
Platelet Function Tests
Platelet function tests were determined by optical whole blood aggregometry in response to arachidonic acid and adenosine diphosphate. the results reflects the percent of active platelets.
Time frame: on day 0 as a baseline and on day 7 and 21 of the study.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.